BARDA VITAL Hub DEV Awards: Up to $250K

Executive Summary

BARDA's VITAL Hub is offering milestone-based, non-dilutive DEV Awards of up to $250K for 6-month therapeutics development projects. Early-stage biotech companies and academic innovators worldwide may apply. Preliminary applications are due October 30, 2026 at 11:59 PM in the applicant's local time zone.

Book a Free Fit Call

Each award covers a single 6-month project, and indirect costs count toward the $250K cap. The rule that decides fit is scope: the technology must sit within one of five focus areas and serve BARDA's medical countermeasure mission. Monoclonal antibodies, small molecules under 900 Daltons, broad AMR work, gain of function research, and oncology or chronic disease programs are out of scope. A preliminary application is the first step. Full applications are by invitation only.

Solicitation at a Glance

• Agency: Biomedical Advanced Research and Development Authority (BARDA), through VITAL Hub, part of the BARDA Accelerator Network
• Opportunity: Annual Non-Dilutive Funding Awards for Development, Evaluation, and Validation of Innovative Therapeutics Solutions (DEV Awards)
• Award Vehicle: Milestone-based non-dilutive award for 6-month projects
• Funding: Up to $250K per award; indirect costs are permitted but count toward the $250K cap
• Technology Maturity: Not stated. Funds may support proof-of-concept work or advance a technology to its next value inflection point.
• Due date: October 30, 2026, 11:59 PM in your local time zone

Think your company qualifies? Talk with BW&CO before the October 30 deadline.

Book a Free Fit Call

What Is the VITAL DEV Awards Program?

VITAL Hub is part of the BARDA Accelerator Network. The DEV Awards provide non-dilutive funding for the development, evaluation, and validation of therapeutics technologies relevant to BARDA's mission. Each awardee also gets project management and regular mentoring during the 6-month project, plus access to BARDA subject matter experts coordinated by the VITAL Lead Mentor.

Parts of the VITAL page still show older text, including a notice that applications are closed and references to 2025 review cycles. Other parts say the solicitation opens August 5, 2026 and closes October 30, 2026 at 11:59 PM. We recommend confirming the current status with VITAL at info@vitalhubhealth.com before you submit.

What Problem Is BARDA Trying to Solve?

BARDA develops medical countermeasures against acute threats. Through VITAL, it wants therapeutics technologies that deliver drugs more precisely, sustain dosing, treat invasive fungal infections, offer new antiviral options, and make vaccines more effective. VITAL gives preference to multi-use and platform technologies. BARDA does not support research and development in oncology or chronic disease.

Priority Capability Areas: What VITAL Is Looking For

• Targeted Delivery: Delivery to specific cells, tissues, or organs, including mucosa and immune-privileged sites such as the eyes, brain and CNS, and reproductive organs.
• Injectable Delivery (Sustained and Controlled): Sustained, controlled injectable delivery for medical countermeasures, such as biodegradable depots and nanoparticles.
• Antifungals: First-in-class, broad-spectrum candidates for invasive fungal infections. Only small molecules or peptides are eligible; vaccines, antibody-based treatments, and topical treatments are out of scope. Applicants must outline a Target Product Profile.
• Antiviral Therapeutics: In scope are programmable RNA antivirals, decoy receptors, glycan traps, and broad-spectrum antiviral peptides. Monoclonal antibodies and small molecule drugs under 900 Daltons, including nucleotide and nucleoside analogues, are out of scope and fall under the SMART Antiviral Prize.
• Vaccine Scaffolds: Multi-antigen structures, such as protein nanoparticles or polymer matrices, that improve vaccine efficacy.

Funding and Award Terms

• Award size: Non-dilutive funding of up to $250K.
• Indirect costs: Permitted, but they count toward the $250K cap.
• Project length: Milestones are expected to be completed within 6 months of the project start.
• Allowable expenses: Direct costs for development, evaluation, or validation, and labor for personnel or contract research organizations.
• Reporting: Quarterly reports tied to milestones, plus a final report.

Eligibility Requirements and Participation

• Who may apply: Early-stage biotech companies as well as academic and other innovators globally.
• SAM.gov: Registration is not required.
• Accelerator Program: You may apply to both the VITAL Accelerator Program and DEV funding; the two are reviewed independently.
• Gain of function: Not supported.
• AMR: VITAL will not fund AMR technologies broadly under this solicitation, except antifungal small molecules and peptides.
• Oncology and chronic disease: Out of scope.

How to Apply

• Confirm your focus area: Match your technology to one of the five focus areas and check the antiviral and antifungal exclusions.
• Watch the info session: VITAL offers an on-demand recording of its info session.
• Prepare antifungal materials: If you apply under Antifungals, outline a Target Product Profile covering the indication and target patient population.
• Submit a preliminary application: Apply through the VITAL application portal by 11:59 PM in your local time zone on October 30, 2026.
• Find collaborators if needed: VITAL offers a DEV Teaming page for finding partners.

What Happens After You Submit?

VITAL reviews preliminary applications for support of BARDA's mission, how unique the innovation is and whether it addresses unmet needs, and whether the funds can advance the technology to its next value inflection point. Applicants who advance are invited to submit a full application. Full applications are by invitation only. VITAL has not posted 2026 notification dates, so confirm the timeline with VITAL.

Is This Opportunity a Good Fit for Your Company?

• Your technology fits a focus area: Targeted delivery, sustained injectable delivery, antifungals, antiviral therapeutics, or vaccine scaffolds.
• It is a platform: Multi-use or platform technologies are preferred.
• Your project is small and defined: You can reach meaningful milestones in 6 months with up to $250K, including indirect costs.
• It serves acute threats: Medical countermeasures against acute threats, not oncology or chronic disease.

It is likely not a fit if your product is a monoclonal antibody, a small molecule antiviral under 900 Daltons, an antibacterial AMR technology, or work that involves gain of function research.

How BW&CO Can Help

BW&CO has helped deep-tech and dual-use founders secure more than $350M in non-dilutive funding. For accelerator-hub awards like the VITAL DEV Awards, we help you:

• Assess focus area fit: Map your technology to the five focus areas and the stated exclusions before you apply.
• Frame BARDA relevance: Present your work in terms of BARDA's medical countermeasure mission and the review criteria.
• Scope a 6-month plan: Define milestones and a budget that fit within the $250K cap, including indirect costs.
• Draft the preliminary application: Write and review a clear, concise submission, including a Target Product Profile for antifungal candidates.
• Prepare for the full application: Plan ahead in case VITAL invites you to submit one.

Plan Your DEV Awards Application

Frequently Asked Questions

How much funding does a DEV Award provide?

Up to $250K per award. Indirect costs are permitted but count toward the cap.

When are applications due?

By 11:59 PM in your local time zone on October 30, 2026. Because some text on the VITAL page is outdated, confirm the current status with VITAL.

How long are DEV Award projects?

Projects are expected to complete their milestones within 6 months of the project start.

Can international applicants and universities apply?

Yes. VITAL accepts applications from early-stage biotech companies and from academic and other innovators globally.

Do I need to register in SAM.gov?

No. VITAL states that SAM.gov registration is not required.

Are monoclonal antibodies or small molecule antivirals eligible?

No. In the Antiviral Therapeutics area, monoclonal antibodies and small molecule drugs under 900 Daltons, including nucleotide and nucleoside analogues, are out of scope. These fall under the SMART Antiviral Prize.

Does VITAL fund antimicrobial resistance technologies?

Not broadly. The exception is first-in-class, broad-spectrum antifungal small molecules or peptides for invasive fungal infections.

Is there a full application?

Yes, by invitation only, for applicants who advance from the preliminary stage.

Can I apply to the VITAL Accelerator Program and DEV funding?

Yes. VITAL reviews each application independently.

Can BW&CO help with a DEV Awards application?

Yes. BW&CO can help you check your fit against the focus areas, scope a 6-month milestone plan within the $250K cap, and draft a clear preliminary application. Eligibility decisions rest with VITAL and BARDA. Book a call with our team.

Source: VITAL Hub DEV Awards (vitalhubhealth.com)